THE SCIENCE
Most tools for the mind work on one system at a time. Therapy works on conscious thought patterns. Meditation trains attention and emotional regulation. SSRIs adjust a single neurotransmitter. Ketamine acts on one receptor. Each reaches something real. None reaches everything at once.
It blocks the patterns locked in the subcortical structures beneath conscious awareness, triggers deep structural and functional neuroplasticity in the brain’s emotional architecture, releases weight stored in the limbic system, recalibrates mood for weeks, and opens a sustained learning window where new patterns physically set and hold. That is why one experience can accomplish what years of separate interventions cannot.
HOW IT WORKS IN THE BRAIN
Think of your mind as a system running background processes you never chose. Programs written over the course of your life, by experience, environment, and the things that happened before you had words for them. They run silently beneath everything you consciously think and feel. They shape your reactions, your patterns, your decisions. Most interventions work on the interface. Iboga goes into the operating system itself.
01 — THE BACKGROUND PROCESSES SURFACE
The prefrontal cortex quiets. The programs running beneath your awareness become fully visible. You see exactly what has been running you and where it began. Not as intellectual insight. As direct, clear seeing.
Cherian et al., 2024
02 — THE LOCKED CODE RELEASES
Iboga blocks the NMDA receptor, the neurological gate keeping ingrained behaviors and fears locked in the subcortical structures. When this gate opens, patterns that felt permanent become moveable for the first time.
Popik, Layer & Skolnick, 1994
03 — THE EMOTIONAL WEIGHT CLEARS
The kappa-opioid receptor, the brain’s signal for heaviness and dread, switches off. What people have carried releases. Not reframed. Not processed. Cleared. People consistently describe feeling physically lighter afterward.
Maillet et al., 2015
04 — THE SYSTEM RECALIBRATES
Iboga blocks serotonin reuptake, the same mechanism as antidepressants, sustained for weeks by noribogaine, iboga’s active metabolite. Not a temporary lift. A new baseline.
Baumann et al., 2001
05 — THE LEARNING WINDOW OPENS
The brain enters its highest state of receptivity. Think of it as running a full system update. Every new pattern practiced in the weeks that follow physically sets and holds. Iboga sustains theta wave activity, the brain’s optimal learning state, for at least one month after a single experience, confirmed by a 2025 Stanford EEG study.
Lissemore et al., 2025
06 — THE SYSTEM REBUILDS
Iboga triggers massive release of BDNF and GDNF, the brain’s own growth and repair proteins. GDNF is so powerful at restoring neural architecture that pharmaceutical companies have invested hundreds of millions trying to synthesize it for Parkinson’s treatment. Iboga produces it naturally. The changes hold because the brain has literally rebuilt itself.
Marton et al., 2019
HOW IT COMPARES
Every modality below helps real people. The difference is which level of the system each one reaches.
THERAPY
Reaches conscious patterns. Builds insight and new thinking over time.
Does not reach subcortical structures. Does not trigger neuroplasticity. Does not recalibrate mood.
SSRIs
Adjusts serotonin to manage symptoms. Partially recalibrates mood.
Does not reach subcortical structures. Does not trigger neuroplasticity. Requires sustained daily use.
KETAMINE
Opens a brief window at the subcortical level. Partially triggers neuroplasticity.
Effects are temporary without repeated infusions. Does not activate GDNF.
MDMA
Creates emotional openness and reduces fear response. Partially releases limbic weight.
Does not reach subcortical structures at the source. Requires multiple sessions.
IBOGA
Reaches all levels simultaneously. Surfaces subcortical patterns. Releases emotional weight. Recalibrates mood. Opens a sustained neuroplasticity window. Activates BDNF and GDNF. Achieves this in a single experience.
THE EVIDENCE
The 2024 Stanford Nature Medicine study is the most rigorous clinical trial ever conducted on ibogaine. Thirty veterans. Traumatic brain injury. Treatment-resistant PTSD, depression, and anxiety. The hardest cases medicine had. Nothing had worked. They received a single dose of iboga delivered in a traditional ceremonial setting. One month later:
REDUCTION IN PTSD SYMPTOMS
REDUCTION IN DEPRESSION
REDUCTION IN ANXIETY
At twelve months, the results held. Nature Medicine · Stanford · 2024.
Effect sizes of 2.1 to 2.8. For context: in clinical research, an effect size above 0.8 is considered large. These results were two to three times that, the largest effect sizes ever recorded for any treatment of these conditions. The best existing treatments help one in three. This helped four in five.
THE ROOT AND THE CONTAINER
Nearly all research studies ibogaine, one isolated compound extracted from the plant. The traditional Bwiti method uses the whole root bark, which contains more than a dozen active alkaloids working synergistically. The isolated molecule approximates what the whole root creates. The full root goes deeper.
And the molecule is only part of it. The same neuroplastic window that makes the brain ready to change also makes it acutely responsive to everything surrounding the experience: the setting, the music, the guidance, the intentions carried in, and the meaning made in the hours and days that follow. The science explains why iboga opens the door. What you walk through it toward is the work of the ceremony and the integration. This is why container matters as much as compound. And why Lunaire is built the way it is.
HELD WITH COMPLETE CARE
Iboga has a documented interaction with cardiac rhythm. Every Lunaire candidate completes a full cardiac evaluation, including a 12-lead EKG, complete metabolic blood panel, and full medication review, before any retreat is confirmed.
Absolute contraindications include cardiac arrhythmia, QT-related conditions, active liver or kidney disease, schizophrenia, bipolar I disorder, and certain medications including SSRIs, MAOIs, lithium, and benzodiazepines. Anyone who does not clear screening does not proceed.
We know this medicine deeply. We hold it with the seriousness it deserves. If you have any medical history you are uncertain about, raise it in your first conversation. We will tell you clearly whether this is right for you.
SOURCES
Cherian et al. (2024). Nature Medicine 30:373–381.
Popik, Layer & Skolnick (1994). Psychopharmacology 114:672–674.
Baumann et al. (2001). J. Pharmacology & Experimental Therapeutics 297:531–539.
Maillet et al. (2015). Kappa-opioid receptor mechanism.
Marton et al. (2019). Frontiers in Pharmacology 10:193.
Lissemore et al. (2025). Biological Psychiatry: CNNI.